Education
About Us
Working with TipRanks
Follow Us
Cyclo Therapeutics Inc (CYTH)
NASDAQ:CYTH
Top Page
Cyclo Therapeutics
(NASDAQ:CYTH)
33Underperform
Positive Factors
Clinical Trials
The company announced it has completed enrollment for its 108-patient pivotal phase 3 trial of its lead drug candidate.
Patents
The company received notice from the European Patent Office of a decision to grant a European patent application.
Negative Factors
Earnings
EPS was $(0.21), versus our and consensus estimate of $(0.17).
Cyclo Therapeutics (CYTH) vs. S&P 500 (SPY)
Market Cap
$20.73M
Dividend YieldN/A
Average Volume (3M)119.08K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth-8.52%
EPS Growth46.35%
CountryUS
Employees8
SectorHealthcare
Sector Strength79
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.90
Shares Outstanding28,614,000
10 Day Avg. Volume56,174
30 Day Avg. Volume119,082
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.13
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cyclo Therapeutics Business Overview & Revenue Model
Company DescriptionCyclo Therapeutics, Inc. (CYTH) is a biotechnology company focused on developing treatments for rare and serious diseases. Specializing in the use of cyclodextrins, the company aims to advance its proprietary Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C (NPC), a rare genetic disorder. Cyclo Therapeutics operates within the pharmaceutical and healthcare sectors, leveraging its expertise in cyclodextrin technology to address complex medical needs.
How the Company Makes MoneyCyclo Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products, particularly Trappsol® Cyclo™. The company's revenue model includes income from product sales, potential collaborations with other pharmaceutical companies, and licensing agreements. Significant partnerships with research institutions and other biotech companies might also contribute to its earnings, as these collaborations can facilitate the advancement and commercialization of its drug candidates. Additionally, the company may receive funding through grants and research subsidies, given its focus on rare diseases. However, as of now, Cyclo Therapeutics is primarily in the research and development stage, which may limit immediate revenue generation until its products are approved and commercialized.
Cyclo Therapeutics Financial Statement Overview
Summary
Cyclo Therapeutics faces significant financial challenges across income, balance sheet, and cash flow statements. Persistent losses and declining revenues alongside rising liabilities and negative free cash flow highlight the need for strategic reassessment to improve financial health and sustainability.Income Statement
The income statement shows a significant decline in revenue and profitability. The TTM period reveals a negative gross profit margin and a worsening net loss, indicating challenges in cost management and revenue generation. The consistent decline in revenue over the years suggests difficulties in sustaining growth.23
Negative
Balance Sheet
The balance sheet shows a deteriorating financial position with negative stockholders' equity in the latest period. This indicates that liabilities exceed assets, posing a risk to financial stability. The increase in liabilities and the significant drop in equity ratio highlight leverage concerns.15
Very Negative
Cash Flow
The cash flow statement shows negative free cash flow, which has worsened over time. The operating cash flow to net income ratio is negative, indicating cash flow issues. The consistent negative free cash flow growth rate underscores challenges in generating cash from operations.18
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 870.73K | 1.08M | 1.38M | 1.59M | 903.38K | 1.01M | Gross Profit |
| -1.79M | 977.95K | 1.24M | 1.43M | 836.98K | 931.71K | EBIT |
| -24.68M | -20.05M | -15.61M | -14.27M | -8.96M | -7.39M | EBITDA |
| -24.67M | -20.03M | -15.60M | -14.27M | -8.95M | -7.39M | Net Income Common Stockholders |
| -24.80M | -20.06M | -15.28M | -14.31M | -8.92M | -7.67M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 933.46K | 9.25M | 1.54M | 16.61M | 12.85M | 2.78M | Total Assets |
| 2.29M | 13.25M | 4.22M | 19.52M | 14.19M | 4.11M | Total Debt |
| 48.49K | 1.03M | 0.00 | 170.99K | 194.44K | 52.51K | Net Debt |
| -884.97K | -8.21M | -1.54M | -16.44M | -12.65M | -2.73M | Total Liabilities |
| 3.98M | 8.49M | 3.48M | 3.85M | 3.74M | 3.18M | Stockholders Equity |
| -1.70M | 4.76M | 734.54K | 15.67M | 10.45M | 935.98K |
| Cash Flow | Free Cash Flow | ||||
| -26.37M | -16.19M | -15.13M | -15.03M | -8.59M | -6.59M | Operating Cash Flow |
| -22.52M | -16.19M | -15.11M | -15.01M | -8.54M | -6.59M | Investing Cash Flow |
| -2.42K | -2.42K | 38.17K | 14.82K | -14.05K | 36.13K | Financing Cash Flow |
| 21.65M | 23.89M | 6.78K | 18.76M | 18.62M | 7.12M |
Cyclo Therapeutics Technical Analysis
Neutral
0.72
Price Trends
0.79
Negative
0.73
Negative
0.86
Negative
Market Momentum
-0.03
Negative
47.87
Neutral
66.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTH, the sentiment is Neutral. The current price of 0.72 is above the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.79, and below the 200-day MA of 0.86, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 66.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CYTH.
Cyclo Therapeutics Risk Analysis
Cyclo Therapeutics disclosed 31 risk factors in its most recent earnings report. Cyclo Therapeutics reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cyclo Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.11B | 202.33 | 1.52% | ― | 33.97% | ― | |
52 Neutral | $1.53B | ― | 18.68% | ― | 36.00% | 63.50% | |
52 Neutral | $672.10M | ― | -68.76% | ― | -65.98% | 14.00% | |
51 Neutral | $5.26B | ― | -231.63% | ― | 42.53% | -15.29% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
45 Neutral | $69.41M | ― | 91.63% | ― | -79.77% | 10.85% | |
33 Underperform | $20.73M | ― | 184.06% | ― | -8.52% | 46.35% |
* Healthcare Sector Average
Performance Comparison
CYTH
Cyclo Therapeutics
0.72
-0.69
-48.94%
BCRX
BioCryst
6.83
2.22
48.16%
ABUS
Arbutus Biopharma
3.23
0.14
4.53%
AUPH
Aurinia Pharmaceuticals
7.81
2.83
56.83%
AXSM
Axsome Therapeutics
98.86
26.75
37.10%
CLSD
Clearside Biomedical
0.86
-0.43
-33.33%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.